BCL9 and colorectal carcinoma: Taken in conjunction with the fact that the BCL9/9L-KO signature in CRC tumors is associated with a better prognosis, the study points out that the BCL9/9L–β-catenin complex represents a promising potential therapeutic target for treating CRC.